Showing 22 Results
The Impact of COVID-19 on Real-World Health Data and Research
This white paper provides key health care stakeholders, including clinicians, researchers, payers and regulators, with a broad view of how the COVID-19 pandemic may have impacted real-world data (RWD…
Are Value-based Arrangements the Answer We’ve Been Waiting for?
This NPC study explored the use of value-based arrangements as a mechanism for cost containment in the United States, noting the strengths and limitations of these tools.
Little Consistency in Evidence Cited by Commercial Health Plans for Specialty Drug Coverage
Evidence cited by payers in coverage decisions for specialty medicines varies significantly, with health plans only citing the same study in 15% of health plan coverage policies for a given drug and…
Are Payers Ready to Address the Financial Challenges Associated with Gene Therapy?
NPC and the Analysis Group conducted market research to explore payer views of the potential roles that existing and new alternative payment approaches could play in managing the financial risk and…
Peer-reviewed Journal Editors' Views on Real-world Evidence
A study published in the International Journal of Technology Assessment in Health Care reveals that real-world evidence is considered valuable by the editors of peer-reviewed journals—if it meets…
Health Plan Use of Patient Data: From the Routine to the Transformational
As the abundance and variety of patient data elements and sources continue to grow, health plans seek opportunities to deepen insights from multiple sources of patient data to shape care delivery,…
Got CER? Educating Pharmacists for Practice in the Future: New Tools for New Challenges
This study provides an early evaluation of the CER Collaborative's training program's impact on learners’ self-reported abilities to evaluate and incorporate comparative effectiveness research…
Designing Successful Bundled Payment Initiatives
The National Pharmaceutical Council led a study that identified three principles intended to maximize the positive aspects and minimize the negative consequences of bundled payments.
Data, Data Everywhere, But Access Remains a Big Issue for Researchers
This study captures the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers. These limitations can make it harder to conduct high…
Why Is Broader Access to Publicly Funded Data Important?
This infographic illustrates the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers.
2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making
NPC's sixth annual survey of stakeholder views on comparative effectiveness research (CER) and the environment for health care decision-making found that stakeholders continue to have a high…
Developing Evidence that is Fit for Purpose: A Framework for Payer and Research Dialogue
A study published in the September 2015 issue of The American Journal of Managed Care introduces a framework developed by the National Pharmaceutical Council (NPC) and AcademyHealth that could help…
When Does FDAMA Section 114 Apply? Ten Case Studies
There is hesitation to disseminate comparative effectiveness research because of ambiguities in the law that was established to help biopharmaceutical companies engage health plans around real-world…
Translating Comparative Effectiveness Research into Medicaid Payment Policy: Views from Medical and Pharmacy Directors
NPC supported a survey of Medicaid medical and pharmacy directors to better understand how policy makers in the state Medicaid programs view comparative effectiveness research (CER) and how they use…
2015 Comparative Effectiveness Research and the Environment for Health Care Decision-Making
NPC's fifth annual survey, "Comparative Effectiveness Research and the Environment for Health Care Decision-Making," provides a snapshot of stakeholders’ perceptions of the key players in the main…
Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice
This study suggests that changes are needed to enable more consistent translation of research findings into clinical practice.
2014 Comparative Effectiveness Research and the Environment for Health Care Decision-Making
Through this annual survey, NPC has been able to track changes in which organizations are perceived as influential in areas such as prioritizing, funding, conducting and monitoring CER, as well as…
When Is Evidence Sufficient for Decision-Making?
It takes an average of 17 years for new data, or evidence, to become part of routine care, according to the Institute of Medicine. A new study outlines influential factors that impact how quickly new…
Communicating About Comparative Effectiveness Research: A Health Affairs Symposium on the Issues
One of many issues connected with comparative effectiveness research is how the findings will be communicated, particularly if they pertain to prescription drugs and if the findings could be useful…
The State of Comparative Effectiveness Research and the Environment for Health Care Decision Making (2012)
The National Pharmaceutical Council conducted its second annual survey of key health care stakeholders. 95 percent of respondents said that CER was "somewhat" or "very important" to them or their…